Skip to main content
SpringerLink
Log in

Depression in schizophrenia: Current guidelines to treatment

  • Articles
  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

Depressive symptoms and syndromes in schizophrenia are common but heterogeneous with respect to etiology, presentation, course, and treatment. Based on a comprehensive differential diagnosis that identifies ten clinical subgroups, the authors review relevant treatment studies and offer current treatment guidelines. The clinical recommendations focus on addressing underlying problems such as medication side effects and substance abuse, attempting to identify and treat medication-responsive syndromes, and preventing suicide. The categories and treatments presented here are expected to evolve as researchers continue to elucidate clinically meaningful syndromes and to develop specific treatments. Nevertheless, current knowledge suggests that many schizophrenics with depression and depression-like symptoms can be treated effectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference notes

  1. Martin RL, Cloninger CR, Guze SB, et al.: Frequency and differential diagnosis of depressive syndromes in schizophrenia.J Clin Psychiatry 46:9–13, 1985 (sec 2).

    Google Scholar 

  2. Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised). Washington, DC, American Psychiatric Association, 1987.

  3. Bartels SJ, Drake RE: Depressive symptoms in schizophrenia: Comprehensive differential diagnosis.Compr Psychiatry 29:61–74, 1988.

    Google Scholar 

  4. Van Putten T, Marder SR: Behavioral toxicity of antipsychotic drugs.J Clin Psychiatry 48:13–19, 1987 (suppl 9).

    Google Scholar 

  5. Rifkin A, Quitkin F, Kane J, et al.: Are prophylactic antiparkinson drugs necessary?Arch Gen Psychiatry 35:483–489, 1978.

    Google Scholar 

  6. Siris SG: Akinesia and post-psychotic depression: A difficult differential diagnosis.J Clin Psychiatry 48:240–243, 1987.

    Google Scholar 

  7. Van Putten T, May PR: “Akinetic depression” in schizophrenia.Arch Gen Psychiatry 35:1101–1107, 1978.

    Google Scholar 

  8. Van Putten T, Marder SR: Toward a more reliable diagnosis of akathisia (letter).Arch Gen Psychiatry 43:1015–1016, 1986.

    Google Scholar 

  9. Johnson DAW: Studies of depressive symptoms in schizophrenia.Br J Psychiatry 139:89–102, 1981.

    Google Scholar 

  10. Shulte JR: Homicide and suicide associated with akathisia and haloperidol.Am J Forensic Psychiatry 6:3–7, 1985.

    Google Scholar 

  11. Shear K, Frances A, Weiden P: Suicide associated with akathisia and depot fluphenazine treatment.J Clin Psychopharmacol 3:235–236, 1983.

    Google Scholar 

  12. Drake RE, Erhlich J: Suicide attempts associated with akathisia.Am J Psychiatry 142:499–501, 1985.

    Google Scholar 

  13. Carpenter Jr. WT, Stephens JH, Rey AC, et al.: Early intervention vs. continued pharmacotherapy of schizophrenia.Psychopharm Bull 18:21–23, 1982.

    Google Scholar 

  14. Herz MI, Szymanski HV, Simon JC: Intermittent medication for stable schizophrenic outpatients: An alternative to maintenance medication.Am J Psychiatry 139:918–922, 1982.

    Google Scholar 

  15. Marder SR, Van Putten T, Mintz J, et al.: Low and conventional dose maintenance therapy with fluphenazine decanoate: Two year outcome.Arch Gen Psychiatry 44:518–521, 1987.

    Google Scholar 

  16. Fayen M, Goldman MB, Moulthrop MA, et al.: Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.Am J Psychiatry 145:483–486, 1988.

    Google Scholar 

  17. McEvoy JP: A double blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.J Clin Psychiatry 48:20–23, 1987 (Suppl 9).

    Google Scholar 

  18. Nestelbaum Z, Siris SG, Rifkin A, et al.: Exacerbation of schizophrenia associated with amantadine.Am J Psychiatry 143:1170–1171, 1986.

    Google Scholar 

  19. Gelenberg AJ: Treating extrapyramidal reactions: Some current issues.J Clin Psychiatry 48:24–27, 1987 (Suppl 9).

    Google Scholar 

  20. Adler L, Angrist B, Peselow E, et al.: Nonadrenergic mechanisms of akathisia: Treatment with propranolol and clonidine.Psychopharmacol Bull 23:21–25, 1987.

    Google Scholar 

  21. Dupuis B, Catteau J, Dumon JP, et al.: Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia.Am J Psychiatry 144:802–805, 1987.

    Google Scholar 

  22. Bartels M, Heide K, Mann K, et al.: Treatment of akathisia with lorazepam. An open clinical trial.Pharmacopsychiatry 20:51–53, 1987.

    Google Scholar 

  23. Kutcher SP, Mackenzie S, Galarraga, et al.: Clonazepam treatment of adolescents with neuroleptic-induced akathisia. (letter)Am J Psychiatry 144:823–824, 1987.

    Google Scholar 

  24. Danel T, Servant D, Goudemand M: Amitriptyline in the treatment of neuroleptic-induced akathisia.Biol Psychiatry 23:186–188, 1988.

    Google Scholar 

  25. Shalev A, Hermesh H, Munitz H: Severe akathisia causing neuroleptic failure: an indication for lithium therapy in schizophrenia?Acta Psychiatr Scand 76:715–718, 1987.

    Google Scholar 

  26. Small JG, Milstein V, Marhenke JD, et al.: Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.J Clin Psychiatry 48:263–267, 1987.

    Google Scholar 

  27. Marder SR, Van Putten T: Who should receive clozapine?Arch Gen Psychiatry 45:865–867, 1988.

    Google Scholar 

  28. Cohen, JD, Van Putten T, Marder S, et al.: The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.J Clin Psychopharmacol 7:324–329, 1987.

    Google Scholar 

  29. Drake RE, Bartels SJ, Torrey WC: Suicide in Schizophrenia: Clinical approaches, inDepression in Schizophrenics. Edited by Williams R and Dalby JT, New York, Plenum Press, 1989.

    Google Scholar 

  30. Drake RE, Osher FC, Wallach MA: Alcohol use and abuse in schizophrenia: A prospective community study.J Nerv Ment Dis 177:408–414, 1989.

    Google Scholar 

  31. Richard ML, Liskow BI, Perry PJ: Recent psychostimulant use in hospitalized schizophrenics.J Clin Psychiatry 46:79–83, 1985.

    Google Scholar 

  32. Safer DJ: Substance abuse by young adult chronic patients.Hosp Commun Psychiatry 38:511–514, 1987.

    Google Scholar 

  33. Knudsen P, Vidmar T: Cannabis and neuroleptic agents in schizophrenia.Acta Psychiat Scand 69:162–174, 1984.

    Google Scholar 

  34. Alterman A, Erdlen F, McLellan AT, Mann S: Problem drinking in hospitalized schizophrenic patients.Addictive Behaviors 5:273–276, 1980.

    Google Scholar 

  35. McCarrick AK, Manderscheid RW, Bertolucci DE: Correlates of acting-out behaviors among young adult chronic patients.Hosp Commun Psychiatry 36:848–853, 1985.

    Google Scholar 

  36. Crowley TJ, Chesluk D, Dilts S, Hart R: Drug and alcohol abuse among psychiatric admissions: A multidrug clinical-toxicologic study.Arch Gen Psychiatry 30:13–20, 1974.

    Google Scholar 

  37. Hellerstein DJ, Meehan B: Outpatient group therapy for schizophrenic substance abusers.Am J Psychiatry 144:1337–1339, 1987.

    Google Scholar 

  38. Kofoed L, Kania J., Walsh T, et al.: Outpatient treatment of substance abusers with other co-existing psychiatric disorders.Am J Psychiatry 143:867–872, 1986.

    Google Scholar 

  39. Ridgely MS, Osher FC, Talbott JA:Chronic mentally ill young adults with substance abuse problems: Treatment and training issues. Baltimore, MD: University of Maryland, School of Medicine, Mental Health Policy Studies, 1987.

    Google Scholar 

  40. Pepper B, Kirshner ML, Ryglewicz H: The young adult chronic population: Overview of a population.Hosp Commun Psychiatry 32:463–467, 1981.

    Google Scholar 

  41. Kofoed L, Keys A: Using group therapy to persuade dual diagnosis patients to seek treatment.Hosp Commun Psychiatry 391209–1211, 1988.

    Google Scholar 

  42. Osher FC, Kofoed L: Treatment of patients with both psychiatric and psychoactive substance use disorders.Hosp Commun Psychiatry 401025–1030, 1989.

    Google Scholar 

  43. Farmer S: Medical problems of chronic patients in a community support program.Hosp Commun Psychiatry 38745–749, 1987.

    Google Scholar 

  44. Koranyi EK: Morbidity and rate of undiagnosed physical illness in a psychiatric clinic population.Arch Gen Psychiatry 36414–419, 1979.

    Google Scholar 

  45. Roca RP, Breakey WR, Fischer PJ: Medical care of chronic psychiatric outpatients.Hosp Commun Psychiatry 38741–745, 1987.

    Google Scholar 

  46. Kulick AR, Ahmed I: Substance-induced organic mental disorders.Gen Hosp Psychiatry 8168–172, 1986.

    Google Scholar 

  47. Dietch JT, Zetin M: Diagnosis of organic depressive disorders.Psychosomatics 24971–979, 1983.

    Google Scholar 

  48. Hall RC, Gardner ER, Popkin MD, et al.: Unrecognized physical illness prompting psychiatric admission: A prospective study.Am J Psychiatry 138629–635, 1981.

    Google Scholar 

  49. Peterson LG, Leipman M, Bongar B: Psychotropic medications in patients with cancer.Gen Hosp Psychiatry 9313–323, 1987.

    Google Scholar 

  50. Silberfarb PM: Psychiatric treatment of the patient during cancer therapy.Ca 38133–137, 1988.

    Google Scholar 

  51. Schwab B, Drake RE, Burghardt EM: Health care of the chronically mentally ill: The culture broker model.Community Ment Health J 24174–184, 1988.

    Google Scholar 

  52. Donlon PR, Rada RT, Arora KK: Depression and the reintegration phase of acute schizophrenia.Am J Psychiatry 1331265–1268, 1976.

    Google Scholar 

  53. Moller H, Von Zerssen D: Depressive state occurring during the neuroleptic treatment of schizophrenia.Schizophr Bulletin 8109–117, 1982.

    Google Scholar 

  54. Straine F, Heger R, Lickpera C: The time structure of depressive mood in schizophrenic patients.Act Psychiatr Scand 6566–73, 1982.

    Google Scholar 

  55. Shanfield S, Tucker G, Harrow M, et al.: The schizophrenic patient and depressive symptomatology.J Nerv Ment Dis 151203–210, 1970.

    Google Scholar 

  56. Leff J, Tress K, Edwards B: The clinical course of depressive symptoms in schizophrenia.Schizophr Research 125–30, 1988.

    Google Scholar 

  57. Salzman C, Green AI, Rodriguez-Villa F, et al.: Benzodiazapines combined with neuroleptics in the management of severe disruptive behavior.Psychosomatics 2717–21, 1986.

    Google Scholar 

  58. Donaldson SR, Gelenberg AJ, Baldessarini RJ: The pharmacologic treatment of schizophrenia: A progress report.Schizophr Bulletin 9504–527, 1983.

    Google Scholar 

  59. Procci WR: Schizoaffective psychosis: Fact or fiction?Arch Gen Psychiatry 331167–1178, 1976.

    Google Scholar 

  60. Pope HG, Lipinski JF, Cohen BM, et al.: Schizoaffective disorder: An invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder.Am J Psychiatry 137921–927, 1980.

    Google Scholar 

  61. Williams PV, McGlashan TH: Schizoaffective psychosis: I. Comparative long-term outcome.Arch Gen Psychiatry 44130–137, 1987.

    Google Scholar 

  62. Levitt JJ, Tsuang MT: The heterogeneity of schizoaffective disorder: Implications for treatment.Am J Psychiatry 145926–936, 1988.

    Google Scholar 

  63. Goodnick PJ, Meltzer HY: Treatment of schizoaffective disorders.Schizophr Bulletin 1030–48, 1984.

    Google Scholar 

  64. Brockington IF, Kendell RE, Kellett JM, et al.: Trials of lithium, chlorpromazine, and amitriptyline in schizoaffective patients.Br J Psychiatry 133162–168, 1978.

    Google Scholar 

  65. Placidi GG, Lenzi A, Lazzerini F, et al.: The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial of 83 patients.J Clin Psychiatry 47490–494, 1986.

    Google Scholar 

  66. Docherty JP, Van Kammen DP, Siris SG, et al.: Stages of onset of schizophrenic psychosis.Am J Psychiatry 135420–426, 1978.

    Google Scholar 

  67. Kayton L, Beck J, Koh SD: Postpsychotic state, convalescent environment, and therapeutic relationship in schizophrenic outcome.Am J Psychiatry 1331269–1271, 1976.

    Google Scholar 

  68. Sachar EJ, Kanter SS, Buie D, et al.: Psychoendocrinology of ego disintegration.Am J Psychiatry 1261067–1078, 1970.

    Google Scholar 

  69. Herz MI, Melville C: Relapse in schizophrenia.Am J Psychiatry 137801–805, 1980.

    Google Scholar 

  70. Carr VK: Recovery from schizophrenia: A review of patterns of psychosis.Schizophr Bulletin 995–121, 1983.

    Google Scholar 

  71. Donlon PT, Blacker KH: Stages of schizophrenic decompensation and reintegration.J Nerv Ment Dis 157200–209, 1973.

    Google Scholar 

  72. Kane JM: Treatment of schizophrenia.Schizophr Bulletin 13133–156, 1987.

    Google Scholar 

  73. Carpenter WT, Heinrichs DW: Intermittent pharmacotherapy of schizophrenia. In Kane J., ed.Drug Maintenance Strategies in Schizophrenia. Washington, DC: American Psychiatric Press, 1984, pp 69–82.

    Google Scholar 

  74. Carpenter WT: Early targeted pharmacotherapeutic intervention in schizophrenia.J Clin Psychiatry 4723–29, 1986 (suppl).

    Google Scholar 

  75. Herz MI: Prodromal symptoms and prevention of relapse in schizophrenia.J Clin Psychiatry 4622–25, 1985 (sec 2).

    Google Scholar 

  76. Hogarty GE, Anderson, CM, Reiss DJ, et al.: Family psychoeducation, social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia.Arch Gen Psychiatry 43633–642, 1986.

    Google Scholar 

  77. Tennant CC: Stress and schizophrenia: A review.Integr Psychiatry 3248–261, 1985.

    Google Scholar 

  78. Lukoff D, Snyder K, Ventura J, et al.: Life events, familial stress and coping in the developmental course of schizophrenia.Schizophr Bulletin 10258–292, 1984.

    Google Scholar 

  79. Leff J, Vaughn C: The role of maintenance therapy and relative's expressed emotion in relapse of schizophrenia: A two year follow-up.Br J Psychiatry 139102–104, 1981.

    Google Scholar 

  80. Goldstein MJ, Rodnick EH, Evans JR, et al.: Drug and family therapy in the aftercare of acute schizophrenics.Arch Gen Psychiatry 351169–1177, 1978.

    Google Scholar 

  81. Drake RE, Osher FC: Using family psychoeducation when there is no family.Hosp Commun Psychiatry 38274–277, 1987.

    Google Scholar 

  82. Andreasen NC, Olsen S: Negative v. positive schizophrenia: Definition and validation.Arch Gen Psychiatry 39789–794, 1982.

    Google Scholar 

  83. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia.Schizophr Bulletin 13261–276, 1987.

    Google Scholar 

  84. Tsuang M:Negative syndrome in schizophrenia: Depressive, drug related, or deficit symptoms. Presented at the University of Calgary conference: Depression in Schizophrenics, July 1988, Calgary, Alberta, Canada.

  85. Carpenter WT Jr, Heinrichs DW, Alphs LD: Treatment of negative symptoms.Schizophr Bulletin 11440–452, 1985.

    Google Scholar 

  86. Crow TJ: Positive and negative symptoms and the role of dopamine.Br J Psychiatry 137383–386, 1980.

    Google Scholar 

  87. Jonstone EC, Crow TJ, Frith CD, et al.: Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.Lancet 1848–851, 1978.

    Google Scholar 

  88. Angrist B, Rotrosen J, Gershon S: Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.Psychopharmacology 7217–19, 1980.

    Google Scholar 

  89. Goldberg, SC: Negative and deficit symptoms in schizophrenia do respond to neuroleptics.Schizophr Bulletin 11453–456, 1985.

    Google Scholar 

  90. Meltzer HY, Sommers AA, Luchins DJ: The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.J Clin Psychopharmacol 6329–338, 1986.

    Google Scholar 

  91. Feinberg SS, Kay SR, Elijovich LR, et al.: Pimozide treatment of the negative schizophrenic syndrome: An open trial.J Clin Psychiatry 49235–238, 1988.

    Google Scholar 

  92. Kane J, Honigfeld G, Singer J, et al.: Clozapine for the treatment-resistant schizophrenic: A Double-blind comparison with chlorpromazine.Arch Gen Psychiatry 45789–796, 1988.

    Google Scholar 

  93. Gerlach J, Luhdorf K: The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs.Psychopharmacologia 44105–110, 1975.

    Google Scholar 

  94. Janowsky DS, Kaled El-Yousef M, Davis JM, et al.: Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.Arch Gen Psychiatry 28185–191, 1973.

    Google Scholar 

  95. Wolkowitz OM, Pickar D, Doran AR, et al.: Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.Am J Psychiatry 14385–87, 1986.

    Google Scholar 

  96. Bacher NM, Lewis HA, Field PB: Combined alprazolam and neuroleptic drug in treating schizophrenia.Am J Psychiatry 1431311–1312, 1986 (letter).

    Google Scholar 

  97. Csernansky JG, Riney SJ, Lombrozo L, et al.: Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.Arch Gen Psychiatry 45655–659, 1988.

    Google Scholar 

  98. Wing J, Brown G:Institutionalism and Schizophrenia. Cambridge: Cambridge University Press, 1970.

    Google Scholar 

  99. Wallace CJ, Nelson CJ, Liberman RP, et al.: A review and critique of social skills training with schizophrenic patients.Schizophr Bulletin 642–63, 1980.

    Google Scholar 

  100. Drake RE, Sederer LI: The adverse effects of intensive treatment of chronic schizophrenia.Compr Psychiatry 27313–326, 1986.

    Google Scholar 

  101. Schooler C, Spohn HE: Social dysfunction and treatment failure in schizophrenia.Schizophr Bulletin 885–98, 1982.

    Google Scholar 

  102. Siris SG, Rifkin A, Reardon GT, et al.: Stability of the post-psychotic depression syndrome.J Clin Psychiatry 4786–88, 1986.

    Google Scholar 

  103. Schwartz CC, Myers JK: Life events and schizophrenia: Impact of life events on symptom configuration.Arch Gen Psychiatry 341242–1245, 1977.

    Google Scholar 

  104. Teague G, Drake RE, Bartels SJ: Stress in schizophrenia: A review of models and research.Stress Medicine 5153–165, 1989.

    Google Scholar 

  105. Convit A, Jaeger J, Lin SP, et al.: Predicting assaultiveness in psychiatric inpatients: A pilot study.Hosp Commun Psychiatry 39429–434, 1988.

    Google Scholar 

  106. Tardiff K, Sweillam A: Assault, suicide and mental illness.Arch Gen Psychiatry 37164–169, 1980.

    Google Scholar 

  107. Sorgi PJ, Ratey JJ, Polakoff S: Beta-andrenergic blockers for control of aggressive behaviors in patients with chronic schizophrenia.Am J Psychiatry 143775–776, 1986.

    Google Scholar 

  108. Tupin JP, Smith DB, Classon TL, et al.: Long-term use of lithium in aggressive prisoners.Compr Psychiatry 14311–317, 1973.

    Google Scholar 

  109. Morand C, Young CN, Ervin FR: Clinical response of aggressive schizophrenics to oral tryptophan.Biol Psychiatry 18575–578, 1983.

    Google Scholar 

  110. Hakola HP, Laulumaa VA: Carbamazepine in the treatment of violent schizophrenics.Lancet 11358, 1982.

    Google Scholar 

  111. Klein E, Bental E, Lerer B, et al.: Carbamazepine and haloperidol v. placebo and haloperidol in excited psychoses.Arch Gen Psychiatry 41165–170, 1984.

    Google Scholar 

  112. Keats MM, Mukherjee S: Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder.J Clin Psychiatry 49117–118, 1988.

    Google Scholar 

  113. Eichelman B: Toward a rational pharmacotherapy for aggressive and violent behavior.Hosp Commun Psychiatry 3931–39, 1988.

    Google Scholar 

  114. Becker RE, Colliver JA, Verhulst SJ: Diagnosis of secondary depression in schizophrenia.J Clin Psychiatry 464–8, 1985 (sec 2).

    Google Scholar 

  115. Siris SG, Morgan V, Fagerstrom R, et al.: Adjunctive imipramine in the treatment of postpsychotic depression.Arch Gen Psychiatry 44533–539, 1987.

    Google Scholar 

  116. Siris SG, van Kammen DP, Docherty JP: Use of antidepressant drugs in schizophrenia.Arch Gen Psychiatry 351368–1377, 1978.

    Google Scholar 

  117. Singh AN, Saxena B, Nelson HL: A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology.Curr Ther Res 23485–501, 1978.

    Google Scholar 

  118. Prusoff BA, Williams DH, Weismann MM, et al.: Treatment of secondary depression in schizophrenia.Arch Gen Psychiatry 36569–575, 1979.

    Google Scholar 

  119. Waehrens J, Gerlach J: Antidepressant drugs in anergic schizophrenia.Acta Psychiatr Scand 61438–444, 1980.

    Google Scholar 

  120. Kurland AA, Nagaraju A: Viloxazine and the depressed schizophrenic: Methodological issues.J Clin Pharmacol 2137–41, 1981.

    Google Scholar 

  121. Becker RE: Implications of the efficacy of thiothixene and a chlorpromazine-imipramine combination for depression in schizophrenia.Am J Psychiatry 140208–211, 1983.

    Google Scholar 

  122. Abrams R:Electroconvulsive Therapy. New York, Oxford University Press, 1988.

    Google Scholar 

  123. Delva NJ, Letemendia FJJ: Lithium treatment in schizophrenia and schizoaffective disorders.Br J. Psychiatry 141387–400, 1982.

    Google Scholar 

  124. Brenner R, Shopshin B: The use of MAOI's in schizophrenia.Biol Psychiatry 15633–647, 1980.

    Google Scholar 

  125. Salzman C: The use of ECT in the treatment of schizophrenia.Am J Psychiatry 1371032–1041, 1980.

    Google Scholar 

  126. Taylor PJ, Fleminger JJ: ECT for schizophrenia.Lancet 11380–1382, 1980.

    Google Scholar 

  127. Brandon S, Cowley C, McDonald P, et al.: Leicester ECT trial: Results in schizophrenia.Br J Psychiatry 146177–183, 1985.

    Google Scholar 

  128. Siris SG, Cooper TB, Rifkin AE, et al.: Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.Am J Psychiatry 139104–106, 1982.

    Google Scholar 

  129. Nelson JC, Jatlow PI: Neuroleptic effect of desipramine steady-state plasma concentration.Am J Psychiatry 1371232–1234, 1980.

    Google Scholar 

  130. Klein DF, Gittleman R, Quitkin F, et al.: Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children. Baltimore, Williams and Wilkins, 1980, pp. 230–231, 445–446.

    Google Scholar 

  131. Akiskal HS: Dysthymic disorder: Psychopathology of proposed depressive subtypes.Am J Psychiatry 14811–20, 1983.

    Google Scholar 

  132. Frank JD:Persuasion and Healing. Baltimore, Johns Hopkins University Press. 1973.

    Google Scholar 

  133. Drake RE, Gates C, Cotton PG, et al.: Suicide among schizophrenics: Who is at risk?J Nerv Ment Dis 172613–617, 1984.

    Google Scholar 

  134. Anthony WA, Cohen MR, Cohen BF: Philosophy, Treatment Process, and Principles of the Psychiatric Rehabilitation Approach, inDeinstitutionalization. Edited by Bachrach L. San Francisco, Jossey-Bass, 1983.

    Google Scholar 

  135. Stone AA, Eldred SH: Delusion formation during the activation of chronic schizophrenic patients.Arch Gen Psychiatry 1177–179, 1959.

    Google Scholar 

  136. Wing JK: Psychosocial factors affecting the long-term course of schizophrenia. InPsychosocial Treatment of Schizophrenia. Edited by Strauss JS, Boker W, Brenner HD. Toronto, Hans Huber, 1987.

    Google Scholar 

  137. Cotton PG, Drake RE, Gates C: Critical treatment issues in suicide among schizophrenics.Hosp Commun Psychiatry 36534–536, 1985.

    Google Scholar 

  138. Breier A, Astrachan BM: Characterization of schizophrenic patients who commit suicide.Am J Psychiatry 141206–209, 1984.

    Google Scholar 

  139. Bernheim K, Lehman AF:Working with Families of the Mentally Ill. New York, Guilford Press, 1985.

    Google Scholar 

  140. Terkelson KG: The evolution of family responses to mental illness through time, inFamilies of the Mentally Ill: Coping and Adaptation. Edited by Hatfield AB, Lefley HP. New York, Guilford, 1987.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. the New Hampshire-Dartmouth Psychiatric Research Center, USA

    Stephen J. Bartels M.D. (Research Associate)

  2. Dartmouth Medical School, USA

    Stephen J. Bartels M.D. (Research Associate) &  Robert E. Drake M.D., Ph.D. (Director of the New Hampshire-Dartmouth Psychiatric Research Center and Associate Professor of Psychiatry)

Authors
  1. Stephen J. Bartels M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Drake M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartels, S.J., Drake, R.E. Depression in schizophrenia: Current guidelines to treatment. Psych Quart 60, 337–357 (1989). https://doi.org/10.1007/BF01064357

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01064357

Keywords

Search

Navigation